Abstract: Metabolic dysfunction-related steatotic liver disease (MASLD), or non-alcoholic fatty liver disease (NAFLD), is becoming a significant complication of obesity and type 2 diabetes mellitus. The antidiabetic agents that have demonstrated positive outcomes in metabolic health and have demonstrated potential in MASLD are sodium-glucose co-transporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA). This is a systematic review and synthesis of the existing evidence on endocrinology of combined SGLT2i and GLP-1RA treatment in MASLD. Review of the literature was carried out in PubMed, MEDLINE, and ClinicalTrials.gov until September 2025........
[1]. Alamri, Z. Z., & Melebary, S. J. (2024). Protective Effects Of Suberoylanilide Hydroxamic Acid And Dapagliflozin Administration On Liver Of Diabetic Rats.
[2].
Kuchay, M. S., Krishan, S., Mishra, S. K., Farooqui, K. J., Singh, M. K., Wasir, J. S., ... & Mithal, A. (2018). Effect Of Empagliflozin On Liver Fat In Patients With Type 2 Diabetes And Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial). Diabetes Care, 41(8), 1801-1808.
[3].
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., ... & Harrison, S. A. (2021). A Placebo-Controlled Trial Of Subcutaneous Semaglutide In Nonalcoholic Steatohepatitis. New England Journal Of Medicine, 384(12), 1113-1124.
[4].
Rosenstock, J., Frías, J. P., Rodbard, H. W., Tofé, S., Sears, E., Huh, R., ... & Patel, H. (2023). Tirzepatide Vs Insulin Lispro Added To Basal Insulin In Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial. Jama, 330(17), 1631-1640.